TAVANTA Trademark

Trademark Overview

On Friday, July 23, 2021, a trademark application was filed for TAVANTA with the United States Patent and Trademark Office. The USPTO has given the TAVANTA trademark a serial number of 90845441. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Sunday, November 23, 2025. This trademark is owned by Tavanta Therapeutics, Inc.. The TAVANTA trademark is filed in the Pharmaceutical Products category with the following description:

Housemark for a full line of prescription pharmaceuticals for the treatment of cancer, anal fissures, cystic fibrosis; pharmaceuticals for treatment of cancer, and cystic fibrosis; pharmaceuticals exhibiting efficient drug release for the treatment of cancer, cystic fibrosis, and anal fissures
tavanta

General Information

Serial Number90845441
Word MarkTAVANTA
Filing DateFriday, July 23, 2021
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateSunday, November 23, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 7, 2023

Trademark Statements

Goods and ServicesHousemark for a full line of prescription pharmaceuticals for the treatment of cancer, anal fissures, cystic fibrosis; pharmaceuticals for treatment of cancer, and cystic fibrosis; pharmaceuticals exhibiting efficient drug release for the treatment of cancer, cystic fibrosis, and anal fissures

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, September 23, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameTavanta Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressRadnor, PA 19087
Party NameTavanta Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressRadnor, PA 19087

Trademark Events

Event DateEvent Description
Tuesday, July 27, 2021NEW APPLICATION ENTERED
Thursday, September 23, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, April 18, 2022ASSIGNED TO EXAMINER
Monday, April 18, 2022NON-FINAL ACTION WRITTEN
Monday, April 18, 2022NON-FINAL ACTION E-MAILED
Monday, April 18, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, October 18, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, October 18, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, October 19, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, October 27, 2022SUSPENSION LETTER WRITTEN
Thursday, October 27, 2022LETTER OF SUSPENSION E-MAILED
Thursday, October 27, 2022NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Tuesday, November 29, 2022TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Monday, January 30, 2023ASSIGNED TO LIE
Monday, January 30, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, January 30, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, January 30, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, February 15, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, March 7, 2023PUBLISHED FOR OPPOSITION
Tuesday, March 7, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 2, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, November 2, 2023SOU TEAS EXTENSION RECEIVED
Thursday, November 2, 2023SOU EXTENSION 1 FILED
Thursday, November 2, 2023SOU EXTENSION 1 GRANTED
Saturday, November 4, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, May 2, 2024SOU TEAS EXTENSION RECEIVED
Thursday, May 2, 2024SOU EXTENSION 2 FILED
Thursday, May 2, 2024SOU EXTENSION 2 GRANTED
Friday, May 3, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, November 4, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, November 5, 2024SOU EXTENSION 3 FILED
Tuesday, November 5, 2024SOU EXTENSION 3 GRANTED
Monday, November 4, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, May 2, 2025SOU TEAS EXTENSION RECEIVED
Friday, May 2, 2025TEAS REQUEST TO DIVIDE RECEIVED
Tuesday, September 30, 2025CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, November 17, 2025CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, May 2, 2025DIVISIONAL REQUEST RECEIVED
Monday, November 24, 2025DIVISIONAL PROCESSING COMPLETE
Friday, May 2, 2025SOU EXTENSION 4 FILED
Monday, November 24, 2025SOU EXTENSION 4 GRANTED
Monday, November 24, 2025ABANDONMENT - NO USE STATEMENT FILED
Monday, November 24, 2025CORRECTED NOA E-MAILED
Tuesday, November 25, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, November 25, 2025ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED

Related Keywords

tavanta treatment pharmaceuticals cystic fibrosis cancer fissures anal efficient drug release